Cambridge BRC

NIHR Comprehensive Cambridge Biomedical Research Centre

Latest News

Cambridge scientists identify the first patient with a thyroid receptor alpha defect

Researchers from the Cambridge BRC have described the first person with a defect in the thyroid hormone receptor alpha gene (THRA). The findings boost our understanding of the relative roles of alpha and beta thyroid receptors in different tissues, and should help inform the development of drugs specific to each receptor type. [Read more...]

Reprogrammed oestrogen binding linked to more aggressive breast cancer

SCIENTISTS based at Cancer Research UK’s Cambridge Research Institute have discovered how receptors for the female sex hormone oestrogen attach to a different part of the DNA in breast cancer patients who are more likely to relapse, according to a study published in Nature on 4th January*. [Read more...]
  • JohnBradley_Still

    Dr. John Bradley
    Director

  • ProfChatterjee_Still

    Professor Krish Chatterjee
    Deputy Director

In 2007, Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge was one of only five partnerships to be awarded a comprehensive Biomedical Research Centre by the National Institute for Health Research (NIHR).

Biomedical Research Centres are leaders in scientific translation, receiving substantial levels of NIHR investment to transform fundamental biomedical research into clinical research that will benefit patients. We are all early adopters of new insights in technologies, techniques and treatments for improving health.

We lead the NIHR Comprehensive Cambridge BRC, working with our highly-skilled teams on eleven transformative, themed programmes on and around the Addenbrooke's campus.

The NIHR Comprehensive Cambridge BRC fosters interdisciplinary initiatives and innovates research training and learning to generate new ideas and attract talented individuals. Since its inception, our centre has evolved into a coherent, democratic organisation that enables, and adds value to, scientific research. It provides an intellectual home and core critical mass for world class translational research, supported by a high degree of public involvement, and connects the laboratory bench to the treatment of patients in and out of hospital.

Cambridge BRC investment has facilitated, and in many cases provided full investment for a wide-reaching research infrastructure that includes the Addenbrooke's Clinical Research Centre, Core Biomedical Assay Laboratory, the Eastern Sequence and Informatics Hub (EASIH), Cambridge NIHR Genomics CoreLab, the Herchel Smith Building for Brain and Mind Sciences, MRI Core, PET/CT, and the Human Tissue Bank. Without support via our NIHR funding many of these facilities, now used widely across the research campus, would not be available.

We recognise that commercial collaborations and activities are central to our success and are pleased to be working in partnership with industry and a range of public sector and charitable partners. We would like to take this opportunity to acknowledge the vital contribution made by members of the public who get involved via Cambridge BioResource and the other organisations; collectively they have already recruited thousands of healthy volunteers and participants to support us.

We hope this website will enable you to gain a deeper understanding into the NIHR Comprehensive Cambridge BRC, to gauge our success to date and, perhaps, to get involved with our future programmes.

John Bradley & Krish Chatterjee
May 2011

 

 

PageBanners: 
Rightnav: 
Highlights Urological Cancer: David Neal Funding from the BRC has been used to develop and support the biorepository and to ensure optimum collection of tissue for translational research into prostate cancer. Read more...